S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:MBIO

Mustang Bio - MBIO Stock Forecast, Price & News

$0.75
+0.01 (+1.35%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.68
$0.78
50-Day Range
$0.55
$0.79
52-Week Range
$0.51
$3.09
Volume
667,729 shs
Average Volume
890,638 shs
Market Capitalization
$77.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Mustang Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
877.6% Upside
$7.33 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.50mentions of Mustang Bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.85) to ($0.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

736th out of 1,135 stocks

Pharmaceutical Preparations Industry

372nd out of 557 stocks

MBIO stock logo

About Mustang Bio (NASDAQ:MBIO) Stock

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Analysts Set New Price Targets

MBIO has been the topic of several research reports. B. Riley reduced their price target on shares of Mustang Bio from $5.00 to $4.00 in a research report on Thursday, July 14th. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Mustang Bio in a report on Friday, May 20th.

Mustang Bio Trading Up 1.6 %

Shares of NASDAQ:MBIO traded up $0.01 during trading hours on Friday, hitting $0.75. 667,729 shares of the company traded hands, compared to its average volume of 890,638. The company's 50 day moving average price is $0.64 and its 200 day moving average price is $0.79. Mustang Bio has a 12 month low of $0.51 and a 12 month high of $3.09. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.51 and a current ratio of 11.51.

Mustang Bio (NASDAQ:MBIO - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Sell-side analysts expect that Mustang Bio will post -0.85 earnings per share for the current year.

Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Stock News Headlines

Recap: Mustang Bio Q2 Earnings
Mustang Bio, Inc. (MBIO)
See More Headlines
Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Company Calendar

Last Earnings
11/12/2021
Today
8/13/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBIO
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+877.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-66,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.19 per share

Miscellaneous

Free Float
100,986,000
Market Cap
$77.30 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Mr. Michael S. Weiss Esq. (Age 56)
    Exec. Chairman
    Comp: $60k
  • Dr. Manuel Litchman M.D. (Age 68)
    Pres, CEO & Director
    Comp: $675.85k
  • Mr. Eliot M. Lurier CPA (Age 64)
    Interim Chief Financial Officer
  • Dr. Knut Niss
    Chief Technology Officer
  • Mr. Matthew Wein J.D.
    VP & Gen. Counsel
  • Ms. Debra Manning SPHR
    Sr. VP of HR
  • Mr. Scott Smith M.B.A.
    Exec. Director and Head of Alliance & Program Management
  • Dr. Bruce Dezube M.D.
    Sr. VP & Head of Clinical Devel.
  • Ms. Robyn M. Hunter (Age 60)
    Corp. Sec.













MBIO Stock - Frequently Asked Questions

Should I buy or sell Mustang Bio stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBIO shares.
View MBIO analyst ratings
or view top-rated stocks.

What is Mustang Bio's stock price forecast for 2022?

4 equities research analysts have issued 1-year price targets for Mustang Bio's shares. Their MBIO share price forecasts range from $4.00 to $11.00. On average, they predict the company's share price to reach $7.33 in the next year. This suggests a possible upside of 877.6% from the stock's current price.
View analysts price targets for MBIO
or view top-rated stocks among Wall Street analysts.

How have MBIO shares performed in 2022?

Mustang Bio's stock was trading at $1.66 on January 1st, 2022. Since then, MBIO shares have decreased by 54.8% and is now trading at $0.7501.
View the best growth stocks for 2022 here
.

When is Mustang Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our MBIO earnings forecast
.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) released its earnings results on Friday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01.

What other stocks do shareholders of Mustang Bio own?

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.23%), JPMorgan Chase & Co. (1.50%), Ikarian Capital LLC (0.24%), Virtu Financial LLC (0.13%), Northern Trust Corp (0.12%) and Envestnet Asset Management Inc. (0.08%). Insiders that own company stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends
.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $0.75.

How much money does Mustang Bio make?

Mustang Bio (NASDAQ:MBIO) has a market capitalization of $77.30 million. The company earns $-66,370,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Mustang Bio have?

The company employs 102 workers across the globe.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The official website for the company is www.mustangbio.com. The company can be reached via phone at (781) 652-4500 or via email at ir@mustangbio.com.

This page (NASDAQ:MBIO) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.